Preliminary results of dulaglutide treatment in patients with non-alcoholic fatty liver disease (DEMOS study)

65 patients with nonalcoholic fatty liver disease (NAFLD) were included in open-label observative prospective cohort study. Mean age was 54.8 ± 10.5 y. o. All patients were treated with metformin before and during the study. All patients were treated by GLP-1 receptor agonist dulaglutide subcutaneously weekly 26 weeks. Patients of group with type 2 diabetes were treated with dulaglutide 0.75 mg weekly 2 weeks, than 1.5 weekly 24 weeks. Patients of group without diabetes were treated by dulaglutide 0.75 mg weekly 4 weeks, than 1.5 weekly 22 weeks. Both groups of patients were demonstrated significant reduce of body weight, BMI, waist circumference, glucose, HbA1c, insulin resistance indexes, transaminases and gamma-glutamyltranspeptidase activity. Fatty liver index and liver stiff ness also decreased after treatment. We can conclude that dulaglutide treatment in NAFLD patients decreases body wieight, improves glucose and lipid metabolism and decreases inflammatory activity of steatohepatitis.

1. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. 2016; 20:205–214.

2. Bellentani S. Th e epidemiology of nonalcoholic fatty liver disease. Liver Int. 2017; 37(Suppl 1):81–84.

3. Lucas C, Lucas G, Lucas N, Krzowska-Firych J, Tomasiewicz K. A systematic review of the present and future of non-alcoholic fatty liver disease. Clin Exp Hepatol. 2018 Sep;4(3):165–174. doi: 10.5114/ceh.2018.78120.

4. Estes C, Anstee QM, Arias-Loste MT. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018 Jun 7. pii: S0168–8278(18)32121–4.

5. Adams LA, Anstee QM, Tilg H, Targher G. Nonalcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017; 66:1138–1153.

6. Santoleri D, Titchenell PM. Resolving the paradox of hepatic insulin resistance. Cell Mol Gastroenterol Hepatol. 2018; https://doi.org/10.1016/j.jcmgh.2018.10.016.

7. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:726–735.

8. Rouabhia S, Milic N, Abenavoli L. Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. Expert Rev Gastroenterol Hepatol. 2014 May;8(4):343–9. doi: 10.1586/17474124.2014.894880.

9. Zhu X., Yan H., Xia M., Chang X., Xu X., Wang L., et al. Metformin attenuates triglyceride accumulation in HepG2 cells through decreasing stearyl-coenzyme A desaturase 1 expression. Lipids Health Dis. 2018;17:114. doi: 10.1186/s12944–018–0762–0.

10. Lin M. J., Dai W., Scott M. J., Li R., Zhang Y. Q., Yang Y., Chen L. Z., Huang X. S. Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway. Oncotarget. 2017;8:108802–108809.

11. Zhou J, Massey S, Story D, Li L. Metformin: an old drug with new applications. Int J Mol Sci. 2018 Sep 21;19(10). pii: E2863. doi: 10.3390/ijms19102863.

12. Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016 May 15;310(10): R885–95. doi: 10.1152/ajpregu.00520.2015.

13. Romantsova T. I. Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity. Obesity and metabolism. 2018, vol. 15, no.1, pp. 3–11. doi: 10.14341/omet201813–11

14. Liu J, Wang G, Jia Y, et al. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease. Diabetes Metab Res Rev. 2015;31:329–335.

15. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016 Feb 13;387(10019):679–90. doi: 10.1016/S0140–6736(15)00803-X.

16. Khoo J, Hsiang J, Taneja R, Law NM, Ang TL. Comparative effects of liraglutide 3 mg vs structured lifestyle modifi cation on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial. Diabetes Obes Metab. 2017 Dec;19(12):1814–1817. doi: 10.1111/dom.13007.

17. Tian F, Zheng Z, Zhang D, He S, Shen J. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. Biosci Rep. 2018 Dec 21;38(6). pii: BSR20181304. doi: 10.1042/BSR20181304.

18. Dutour A, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab. 2016 Sep;18(9):882–91. doi: 10.1111/dom.12680.

19. Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, et al. Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res. 2017 Oct;47(11):1206–1211. doi: 10.1111/hepr.12837.

20. Cusi K, Sattar N, García-Pérez LE, Pavo I, Yu M, Robertson KE, et al. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diabet Med. 2018 Oct;35(10):1434–1439. doi: 10.1111/dme.13697

21. Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Rev. 2019 Feb 15. doi: 10.1111/obr.12839.

22. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.

23. McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-Invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740–751.

24. Ndrepepa G, Kastrati A. Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med. 2016 Dec;4(24):481. doi: 10.21037/atm.2016.12.27

25. Alexander KS, Zakai NA, Lidofsky SD, Callas PW, Judd SE, Tracy RP, Cushman M. Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The reasons for geographic and racial differences in stroke cohort. PLoS One. 2018 Mar 12;13(3): e0194153. doi: 10.1371/journal.pone.0194153. eCollection 2018. PMID: 29529073.